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Abstract In this paper, we investigate the pharmacokinetics and effect of doxorubi-
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into account especially vascular and morphological heterogeneity as well as cellular
and lesion-level pharmacokinetic determinants like P-glycoprotein (Pgp) efﬂux and
cell density. To do this we construct a multi-compartment PKPD model calibrated
from published experimental data and simulate 2-h bolus administrations followed by
18-h drug washout. Our results show that lesion-scale drug and nutrient distribution
may signiﬁcantly impact therapeutic efﬁcacy and should be considered as carefully as
genetic determinants modulating, for example, the production of multidrug-resistance
protein or topoisomerase II. We visualize and rigorously quantify distributions of
nutrient, drug, and resulting cell inhibition. A main result is the existence of signi-
ﬁcant heterogeneity in all three, yielding poor inhibition in a large fraction of the
lesion,andcommensurately increased serumdrugconcentration necessaryforanave-
rage 50% inhibition throughout the lesion (the IC50 concentration). For doxorubicin
the effect of hypoxia and hypoglycemia (“nutrient effect”) is isolated and shown to
further increase cell inhibition heterogeneity and double the IC50, both undesirable.
We also show how the therapeutic effectiveness of doxorubicin penetration therapy
depends upon other determinants affecting drug distribution, such as cellular efﬂux
and density, offering some insight into the conditions under which otherwise pro-
mising therapies may fail and, more importantly, when they will succeed. Cisplatin
is used as a contrast to doxorubicin since both published experimental data and our
simulations indicate its lesion distribution is more uniform than that of doxorubi-
cin. Because of this some of the complexity in predicting its therapeutic efﬁcacy is
mitigated. Using this advantage, we show results suggesting that in vitro monolayer
assaysusingthisdrugmaymoreaccuratelypredictinvivoperformancethanfordrugs
like doxorubicin. The nonlinear interaction among various determinants representing
cell and lesion phenotype as well as therapeutic strategies is a unifying theme of our
results. Throughout it can be appreciated that macroscopic environmental conditions,
notably drug and nutrient distributions, give rise to considerable variation in lesion
response,henceclinicalresistance.Moreover,thesynergyorantagonismofcombined
therapeutic strategies depends heavily upon this environment.
Keywords In silico · Simulation · Pharmacokinetics · Prediction · Therapy
Mathematics Subject Classiﬁcation (2000) 92C45
1 Introduction
While drug resistance to solid tumors is often a consequence of genetic factors, such
as upregulation of anti-apoptotic proteins or overexpression of efﬂux mechanisms,
factors at coarser physiological scales may also profoundly inﬂuence tumor therapeu-
tic response [50]. A tumor is a heterogeneous three-dimensional composite of ﬁbrous
and connective tissues, stromal components, vasculature, and multiple clones of can-
cer cells. Atop this intrinsic heterogeneity is layered the anatomical and functional
irregularity of tumoral vasculature, characterized by erratic ﬂow, collapsed vessels,
diminished oxygen tension, and a large mean tissue-to-vessel distance [5,29,30,34,
54]. As a consequence, the tumor microenvironment is highly variable, marked by
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gradients of nutrient and oxygen, resulting in regions of hypoxia, acidity, and necro-
sis, and heterogeneous proliferation. In order for an anticancer agent to be effective,
it must extravasate, diffuse through lesion tissue, and be transported into cells, where
it must bind to its target and induce cell apoptosis or mitotic inhibition. The tumor
environment is not conducive to these processes [50]. The vessel bed’s blood ﬂow and
spatial distribution hinder uniform extravasation, calling into question the capability
of drug molecules to adequately distribute throughout tissue. Recent experiments in
vitro [38,73,81] and in vivo [40,57] demonstrate limited drug penetration through
tumors, especially highly protein-bound molecules like doxorubicin and paclitaxel.
Once a drug molecule has traversed lesion tissue from its point of extravasation and
is presented to a cancer cell, the path from extracellular space to intracellular target
is fraught with difﬁculties ranging from protonation due to the acidic environment,
whichrendersanthracyclinesincapableoftraversingmembrane,tointracellularremo-
val by drug efﬂux pumps, to cellular processes that effect DNA repair and drug clea-
rance [3,15,31,65,71,79]. In addition to pharmacokinetics, drug pharmacodynamics
isequallyimpaired.Signiﬁcanthypoxiaandhypoglycemiathroughoutmayinducecell
quiescence, reducing the efﬁcacy of cell-cycle chemotherapeutic agents like doxoru-
bicin and cisplatin [18,19]. Hypoglycemia causes the glucose-regulated stress res-
ponse detrimental to the action of topoisomerase II-directed drugs like doxorubicin
[41,49,64,68].
The heterogeneity and three-dimensionality of the tumoral environment presents
a challenge to drug assessment, both during development and in the clinic. Whereas
a particular drug may show marked activity against a particular specimen in vitro,
its potency may vanish or become far less reliable in vivo. This is evidenced by the
differential between positive predictive accuracy of in vitro-assisted therapy selection
(around 70%) and negative predictive accuracy (around 90%), a situation not remar-
kably changed over the years [26,27]. Supraoptimal delivery of drug to cultured cells
eliminates the gauntlet of biobarriers in vivo described above, precluding the varia-
bility they induce. A drug that consistently works in vitro can therefore be expected
to only sometimes work in vivo. Unraveling the myriad interactions of therapeutic
determinants within the complex three-dimensional tumoral environment is evidently
difﬁcult, resulting in high costs of drug development and patient suffering.
Perhapsthecrystalballweareattemptingtobuildisincompletewhenmadeonlyof
glass typically found in experimental labs; computer (in silico) simulations based on
mathematicalmodelingandcalibratedwithexperimentaldatamightfulﬁllakeyaspect
of the lens. A signiﬁcant capability of in silico experimentation (including simulated
assays) is the complete control over and monitoring of the simulated in vivo tumor
environment.Moreover,computermodelingcancreatehypotheticalenvironmentsand
conditions impossible to achieve otherwise, the study of which is nonetheless instru-
mental in unraveling disease and drug mechanisms. This expansive control, founded
upon an adequately mechanistic mathematical basis, could facilitate the discovery of
hypotheses as to why certain drugs or therapeutic strategies would or would not be
effective,potentiallyonapatient-by-patientbasis.Therelativeeaseandcost-efﬁciency
ofperformingsimulationscouldfurthermoreenableathoroughinvestigationofstrate-
gies,revealingtheoptimalamongthem.Thejudiciouscombinationofthisburgeoning
technology with the capabilities of the wet-lab is an attractive development in both
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drugdiscoveryandtheclinicalmanagementofcancerleadingtotheeasingofpatients’
burdens.
The past two decades have witnessed explosive growth in the mathematical and
computational modeling of vascular and avascular tumors [1,4,7–9,13,36,43,44,56,
82]. As the basic elements of tumoral growth models have matured, specialized treat-
ments of angiogenesis and ﬂow [2,46,47,69], drug delivery and response [33,40,52,
66,80], and effects of the tumoral microenvironment [23,45] have been developed.
Somesimulationandanalysishasprovidedgreatinsightusingone-dimensionalmode-
ling(employingcylindricalorsphericalsymmetry)withoutdiscretevasculature.More
recently, powerful numerical methods have been developed so as to simulate multi-
dimensional complex morphological progression and its relation to cell phenotype
and the microenvironment involving, for example, nutrient and biomechanical tissue
response [23,45,82].
Inthepresentpaperweexaminetherapeuticefﬁcacyoftwocommondrugs,cisplatin
anddoxorubicin,inrelationtophenotypicandmicroenvironmentalconditions.Model
parameters govern extracellular drug/tissue diffusivity; cellular uptake, efﬂux, and
metabolism; cellular density; and the effect of nutrient heterogeneity on drug action.
Simulations are performed in a two-dimensional (non-symmetric) setting employing
discrete vasculature, which enables the incorporation of morphological and topologi-
cal inﬂuence on drug and nutrient distributions. The effect of these distributions on
therapeutic efﬁcacy is of special interest. Sinek et al. [66] had earlier performed a
similarinvestigation; however, thepharmacokinetics andpharmacodynamics (PKPD)
component was rudimentary, assuming one homogenous lesion compartment and not
based upon experimentally acquired parameter values. In the present work we imple-
ment an extensive multi-compartment PKPD component whose parameter values are
calibrated via published experimental data. This enables a comparison of the tissue-
and cell-level drug dynamics of the two drugs, and facilitates the generation of hypo-
theses to explain their in vivo characteristics. We ask that the reader consider that if
doxorubicin and cisplatin were discovered only today, the simulations herein could
be seen as providing insight into their anticipated in vivo performance, potentially
streamlining and reducing costs of development. Indeed, the methodology presented
herein could, with additional development, be applied to both established and nascent
drugs to the end of reﬁning clinical trials and assisting in clinical therapeutic strategy
to improve patient comfort and survival.
2 Mathematical model and parameters
2.1 Model description
The multiscale tumor growth and angiogenesis simulator developed by Zheng et al.
[82] is used to grow the lesions upon which we simulate chemotherapy. This is a
nonlinear, continuum scale, two-dimensional growth engine whose accuracy is made
possiblebyanadaptiveﬁniteelementmeshduetoCristinietal.[11].Themeshenables
multi-scale computation for ﬁnely resolving tumor morphology, especially around
importantareassuchasthenecrotic/tumorandtumor/hostinterfacesandaroundcapil-
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lary sprouts. Realistic and heterogenous vasculature through which nutrient and drug
is provided is generated via the angiogenesis model of Anderson and Chaplain [2].
The simulation ﬁeld incorporates three phases (see Fig. 2): viable cancerous tissue,
normal host tissue, and necrotic debris. The lesion/host interface is demarked by thick
black contours, while the microvasculature appears as a web of thin red curves. Dark
interior regions are necrotic debris.
Brieﬂy, nutrient and oxygen are provided through the discrete microvasculature,
which is generated in response to angiogenic regulators produced from perinecrotic
cells.Thisresultsinproliferationand tumorgrowth. The simplesteady-state diffusion
equation
0 = kv(1 − n)δ + Dn∇2n − knn (1)
is used to model nutrient delivery and uptake, where n is the local nutrient normalized
by the intravascular level, kv is a measure of vascular porosity (0 is impermeable,
∞ is completely porous), δ is the Dirac delta function located along the vasculature,
Dn is nutrient diffusivity, and kn is the local rate of consumption by cells [82]. The
characteristicallyhighporosityoftumorvasculatureimpliesaveryhighsettingofkv so
that,essentially,vasculatureprovidesaconstantboundaryconditionof1.Experiments
given in [51] demonstrate that oxygen penetrates approximately 150 mmi n t oi nv i t r o
spheroids before falling to about 10% of serum level. At this point necrosis ensues.
Combiningthiswithadiffusivity Dn ofaround60,000mm2 min−1 [53,70],thenutrient
uptake rate is calculated to be kn = 24 min−1. Waste resulting from necrotic cell
degradation is assumed to be removed via convection towards and through the tumor-
host interface as well as via scavenger cell phagocytosis. In regions where nutrient is
sufﬁcient to maintain viability, mitosis is assumed to be directly proportional to its
concentration,withtheproportionalityconstantdependentupontheaveragecellcycle
time of the malignant population.
Once the tumors are grown, drug administration via the vasculature is simulated by
our multi-compartment pharmacokinetics model, based upon earlier work of [15,17,
20,21]. For cisplatin, there are three compartments corresponding to (1) extracellular,
(2)cytosolic,and(3)DNA-bounddrug.Fordoxorubicin,thereisafourthcompartment
corresponding to intracellular organelles, e.g., lysosomes. The system of equations
governing transport for both drugs (with different parameter values) is
˙ s1 = kv(sv − s1)δ + Ds∇2s1 − k 
12s1 + k 
21(s2/106Vc)
˙ s2 = k12106Vcs1 − k21s2 + k32s3 − k23s2(1 − s3/sm) + k42s4 − k24s2
(2)
˙ s3 = k23s2(1 − s3/sm) − k32s3 − k3s3
˙ s4 = k24s2 − k42s4
where si represents drug concentration in compartment i, kij represents a transfer rate
fromcompartmenti to j,andki representsarateofpermanentremovalfromcompart-
ment i and the system. sv is intravascular drug concentration during bolus, and sm is a
DNAsaturationparameterrelevanttodoxorubicin. Vc isthevolumeofacell(assumed
spherical with diameter 10 mm, yielding Vc = 520 fL cell−1) and appears in the ﬁrst
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two equations to reconcile the dimensions of sv and s1 (mM) with the dimensions of
all other compartments (fmoles/cell). kv and δ are the same as in Eq. (1). The pri-
med rates appearing in the ﬁrst equation are related to their unprimed counterparts
via k 
ij = kij/F where F is the extracellular fraction of whole tissue. Taking a base-
line tumor density of ρ = 1.0E9 cells mL−1, a well-known representative value, in
combination with the cell volume previously quoted results in
F = 1 − ρVc(10−12 mL fL−1)
= 0.48, (3)
also a reasonable value. Finally, Ds is the diffusivity of the drug through extracellular
space.
Bothcisplatinanddoxorubicinpassthroughcellmembraneaccordingtok12 (which
includes possible pump and transporter activity, as do all other rates). From there, the
drugs may efﬂux according to k21 or may bind to DNA according to k23. The kinetics
differ from here for the two drugs. Cisplatin may be removed according to the rate k3,
which destroys the functioning of the drug and repairs the DNA [79]. Doxorubicin,
however,hasanoffrategivenbyk32,andmoreovermaybesequesteredandreleasedby
lysosomes according to k24 and k42 [3,31,59]. Although lysosomal ﬂow to membrane
andexocytosisofsequestereddrugplaysaroleinsomedrugresistantcelllines,weare
not necessarily modeling drug resistance via this function, and so assume this process
to be negligible in accordance with [16]. On the other hand, we are concerned with
the quantity of drug lysosomes can sequester, as this contributes to the cellular uptake
of drug, and hence, its penetration characteristics.
The pharmacodynamics model consists of the Hill-type equation along the lines of
those employed in [20,21]
E =
N(n)
1 + A−1x−m (4)
where E is cell inhibition (1 minus surviving fraction), x is DNA-bound drug-time
product (area under the curve, or AUC), and A and m are phenomenologically ﬁt
parameters. N(n) is a function of nutrient n ranging from 0 to 1 used to mimic the
effectofhypoxiaandhypoglycemia.Resultswithdoxorubicinshowthatcellsindeeper
layersofspheroidsdonotrespondaswelltodrugasdocellsonthesurface,evenwhen
intracellulardruglevelsaretakenintoaccount[18,19].Otherexperimentsdemonstrate
reduced response in monolayer when cells are forced into quiescence due to reduced
oxygen [68]. Still others show that hypoglycemia can deplete topoisomerase II, thus
reducingtheeffectofsomeanthracyclines[64].Theseresultsimplythattheresponseof
cells to doxorubicin in vivo might correlate to the local nutrient, a phenomenon which
we herein refer to as the “nutrient effect.” For our purposes, the exact form of N is
not important. For simplicity, we choose N = np, where p is a phenomenological
parameter derived from the data of [19], and equals 0.4. Since in our model n is
normalized with respect to the intravascular level, it runs from 0 to 1, and thus so
does N. Furthermore, at full nutrient levels, N = 1, and so cell inhibition is maximal.
In our simulations, drug pharmacokinetics (Eqs. 2) is allowed to proceed from bolus
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Table 1 A complete summary of baseline pharmacokinetics and pharmacodynamics parameters
Parameter Description Baseline Value
Dox Cis
Vc Cell volume (fL cell−1) 520 520
ρ Cell density (cells mL−1) 1.0E9 1.0E9
F Interstitial fraction 0.48 0.48
Dn Nutrient/ECM diffusivity (mm2 min−1) 60E3 60E3
Ds Drug/ECM diffusivity (mm2 min−1) 1.0E3 30E3
kn Nutrient metabolism (min−1)2 4 2 4
k12 Drug uptake (min−1) 5.40 0.054
k21 Drug efﬂux (min−1) 5.40 1.56E–3
k23 Drug–DNA binding (min−1) 8.02E5 3.82E–4
k32 Drug–DNA release (min−1) 1.80E3 0.0
k3 Drug–DNA repair (min−1) 0.0 0.015
k24 Lysosomal sequestration (min−1) 10.0 0.0
k42 Lysosomal release (min−1) 0.07 0.0
sm Drug–DNA capacity (fmole) 1.00 ∞
A Phenomenological PD parameter 0.188 7.75
m Phenomenological PD parameter 1.14 1.58
p Nutrient effect parameter 0.4 0.0
Tumor growth and angiogenesis parameters can be found in [82]
initiation to washout 20 h later. During this time the locally varying DNA-bound AUC
is calculated and used to ﬁnd cell inhibition (Eq. 4).
2.2 Pharmacokinetics model parameters
A generally acceptable theoretical setup for performing experiments to measure com-
partmental concentrations (and therefore to derive the rate constants we are after)
is either a suspension or monolayer in an inexhaustible drug-laden medium corres-
ponding to s1. Under these conditions, the relevant model consists of the last three
equations in Eqs. (2), with s1 held constant. We will refer to this model as the modi-
ﬁed version of Eqs. (2). All model parameters and values are summarized in Table 1.
These will be referred to as the baseline values, some of which will be adjusted later
to simulate different tumor characteristics and therapeutic treatments. We emphasize
that parameter values, having been derived from a variety of published experimental
data spanning many years and cell types, correspond to a prototypical tumor and can-
cer cells suitable for the simulations herein, but not necessarily representative of any
particular clinical specimen.
Cisplatinparameters Webeginwithcisplatin,settingk24 andk42 to0sinceweassume
only three compartments, and k32 to 0 since we assume the repair rate k3 is the
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dominant removal rate of DNA-bound drug. k3 is next obtained as follows. In experi-
ments performed by Sadowitz et al. [60], adducts per million nucleotides on isolated
peripheral blood mononuclear cell DNA fall from 75 to 5 and 185 to 40 in2hi n
two different experiments. Thus, assuming the exponential repair model ˙ s3 = k3s3,
we calculate the repair rate to be about 0.015 min−1. An initial estimate of k23 is then
made as follows. Sadowitz shows that for 7 mM cisplatin, in 2 h peripheral blood
mononuclear cells accumulate from about 25 (non-thiol-blocked cells) to 175 (thiol-
blocked cells) adducts per million nucleotides. Assuming that DNA consists of about
1.25E6kbp,thisconvertstofrom1.04E–4to7.27E–4fmolesofPtdockedontheDNA
(1 atom/adduct). Neglecting the cell membrane and supposing DNA to be exposed
directly to the drug, we have the ODE ˙ s3 = 7λ23 − k3s3, where λ23 is a clearance
parameter (fL min−1). The solution is s3 = 7(λ23/k3)(1 − exp(−k3t)). Substituting
valuesofk3 = 0.015 min−1,t = 120 min,and1.04E–4≤ s3 ≤7.27E0–4 fmoleyields
0.27 ≤ λ23 ≤ 1.9f Lm i n −1.Toconvertthistoarateweusetherelationk23 = λ23/Vc,
arriving at 5.19E–4 ≤ k23 ≤ 3.65E–3 min−1. The assumption that DNA was exposed
directly to the cisplatin solution means that this rate is only a bootstrap approximation
and must be reﬁned. We note that the extremely low ratio of adducts per kbp implies
that the saturation capacity of DNA with respect to cisplatin is never approached, and
so set sm to ∞.
Next, we estimate k12 and k21. While doing this we will reﬁne our initial estimate
of k23. The whole procedure involves ﬁtting the best curves to data from Troger et al.
[76](Fig.1a).TrogerexposedhumantonguecarcinomaCAL-27cellsinmonolayerto
four different concentrations of cisplatin and then measured total intracellular amount
of Pt at selected times. This corresponds to s2 + s3 in our model. Beginning with the
previous estimate of k23 and setting s1 to concentrations used by Troger, we adjust k12
and k21 in the modiﬁed version of Eqs. (2) until a good ﬁt of Troger’s data is obtained.
Simultaneously,weadjustk23 tokeeptheDNA-bounddrugtruetoresultsofSadowitz
previously discussed. We remark that the disparity between the inward and outward
rates derived for cisplatin may be due in part to carrier-mediated transport, e.g., the
CTR1 inﬂux transporter.
Doxorubicin parameters Proceeding to doxorubicin we ﬁrst obtain an acceptable
range for k12 and k21 from the literature. For a variety of anthracyclines, including
doxorubicin, initial estimates of cell membrane permeability P are taken from expe-
riments with SU-4 and SU-4R wildtype and resistant human lymphoma cells [17],
fromexperiments withEHR2andEHR2/DNR+wildtypeandresistantEhrlichascites
tumor cells [15,16], and from experiments with MDA-468 breast cancer cells [40].
Therangereportedis2.4 ≤ P ≤1000 mmm i n −1.Therelationk12 = PA c/Vc,where
Ac represents the cell membrane area, can then be used to arrive at an initial range of
1.4 ≤ k12 ≤ 600 min−1, which will be reﬁned later. In the case of passive diffusion,
k21 = k12. We note that these values are far larger than those obtained for cisplatin
previously. More generally, it has been remarked that cell membrane permeability for
cisplatin is much lower than for doxorubicin, etoposide, and vinblastine, although all
four drugs are thought to enter cells by passive diffusion [35].
We next turn our attention to DNA-binding afﬁnity. Given the great DNA afﬁnity
of the anthracyclines, saturability of the DNA must be taken into account, requiring
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Fig. 1 a Data from Troger et al. [76] used to calibrate k12,k21,a n dk23 for the cisplatin model. Parameters
are ﬁt simultaneously to all four curves treated as one set of data. b Cell inhibition ﬁts for Eq. (4)u s i n g
Levasseur’s [42] data on A2780 ovarian cancer cells exposed in monolayer
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an estimate of sm. There is evidence a typical anthracycline molecule intercalation
occludes from 3 to 10 binding sites in a manner that cannot be corrected exactly by a
factor [48,59,74]; however, to a ﬁrst approximation we assume that such a correction
can be applied. Demant and Friche [15] report a DNA binding site concentration of
about 5 mM within a cell volume of 1000 fL, yielding 5 fmoles of sites. A low value
of 0.7 fmoles is obtained by using our assumed value of 1.25E6 kbp and the reported
site exclusion parameter of about 3 from Rizzo et al. [59]. Tarasiuk et al. [74] ﬁnd
that the DNA of human lymphocytes is comprised of about 6.0E6 kbp and that one
intercalating molecule of doxorubicin requires 10 base pairs. Thus, Tarasiuk’s data
implies a factor-corrected quantity of 1 fmole of binding sites, which we take as a
representative value of sm.
DNAbindingkineticsoftheanthracyclinesisnontrivial,perhapsrequiringmultiple
steps and demonstrating sequence speciﬁcity [58,59]. Bearing this in mind, as an
approximation it will sufﬁce to assume non-speciﬁc, one-step binding and unbinding
according to the chemical reaction
drug molecule + DNA bp
koff

kon
intercalated bp.
A representative value for the binding coefﬁcient in the above equation for doxoru-
bicin is reported as kon = 4.2E8 M−1 min−1 and a value of the unbinding coefﬁcient
(identical with k32)a skoff = 1800 min−1 [59]. From kon we calculate a clearance
parameter (as with cisplatin) given as λ23 = konsm= 4.2E8 fL min−1 (being cautious
with the scales of our dimensions). k23 can then be calculated as λ23/Vc,g i v e ni n
Table 1.
We next turn our attention to the rates k24 and k42 governing lysosomal sequestra-
tion. Experiments byHurwitz et al. [31]using U-937 myeloid leukemia cells and their
dox-resistantvariantU-A10showthattheratioofDNA-boundtolysosomallyseques-
tered drug is about 3 (Hurwitz uses daunorubicin, an anthracycline related to doxo-
rubicin). In our modiﬁed model equations with all other parameters set as described
above, the amount of sequestered drug at equilibrium is dependent only upon the ratio
k24/k42.ThisratiofurthermoredoesnotaffecttheequilibriumquantityofDNA-bound
drug. Arbitrarily selecting k24 = 1m i n −1, we ﬁnd that the appropriate DNA-bound
to lysosomally sequestered ratio is obtained by setting k42 to 0.007. Considering that
lysosomalmembranepermeabilityisquitehigh[16],thelysosomallybounddrugmust
achieve equilibrium quickly, which can be modiﬁed by changing k24 while keeping
the ratio k24/k42 constant. We ﬁnd that increasing k24 by a factor of 10 reduces the
time required for the system (Eqs. 2) to achieve 95% of equilibrium value (max95)t o
about 300 min, below which further increases in k24 only reduce this time negligibly.
Thus, we set k24 = 10 and k42 = 0.07.
To reﬁne our initial range of k12 and k21, we use the modiﬁed version of Eqs. (2)
to compare our simulated monolayer uptake proﬁles of total intracellular drug with
thoseofDeGregorioetal.[14]usinghumanEwing’ssarcomaandrhabdomyosarcoma
cells. At 5.40 min−1 both uptake proﬁles and equilibrium values compare favorably
at three test concentrations.
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Drug–tissue diffusivity The last pharmacokinetics parameter values needed are the
diffusivities Ds ofcisplatinanddoxorubicinthroughtumorinterstitium.Formolecules
of their size (dox M.W. = 544, cis M.W. = 300), diffusivity should be about
30,000 mm2 min−1 [53,70]. However, doxorubicin faces particularly severe barriers
due to binding to extracellular constituents such as hyaluronic acid [37,38], and its
diffusivity in some tissues has been estimated to be as low as 1000 mm2 min−1 [40],
which we take as our baseline value.
2.3 Pharmacodynamics model parameters
In order to calibrate the pharmacodynamics model (Eq. 4), we use in vitro data of
Levasseur et al. [42] with A2780 ovarian cancer cells exposed in monolayer to both
doxorubicin and cisplatin over a range of times and concentrations. We assume the
previously discussed modiﬁed pharmacokinetics model along with the values deri-
ved, and simulate Levassuer’s exposures followed by approximately 24 h of drug
washout in drug-free medium (s1 is set to 0). During this time, DNA-bound AUC is
calculated. These data are then used in conjunction with Levasseur’s surviving frac-
tion data to ﬁt the parameters A and m in Eq. (4) using Microsoft Excel (Fig. 1b).
During this process, nutrient is assumed plentiful (n = 1), thus bypassing the nutrient
effect.
3 Computational simulations
3.1 Non-dimensionalization and numerical methods
Non-dimensionalization of Eqs. 2 is via the length- and time-scales
L =

Ds/k12 T = k−1
12
with the compartmental concentrations transformed as
s1 = s1/sv s2 = s2/1E6Vcsv s3 = s3/1E6Vcsv
s4 = s4/1E6Vcsv sm = sm/1E6Vcsv
resulting in
˙ s1 = kv(1 − s1)δ + ∇
2
s1 − s1/F + k21s2/F
˙ s2 = s1 − k21s2 + k32s3 − k23s2(1 − s3/sm) + k42s4 − k24s2
(5)
˙ s3 = k23s2(1 − s3/sm) − k32s3 − k3s3
˙ s4 = k24s2 − k42s4
The numerical methods for tumor growth and angiogenesis have been described in
detail in Zheng et al. [82]. For the reaction–diffusion equations (Eqs. 2) we ﬁrst use
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Strangsplitting.Thenthetrapezoidalruleisappliedtothereactionpart,andtheCrank-
Nicolson scheme, to the diffusion part. For a description of these methods, see Tyson
et al. [78] and references therein.
3.2 In silico experiments
Four in silico experiments are performed in the following manner:
1. Three simulated tumors are grown using Zheng et al.’s model [82]. Each lesion
represents one replication of each experiment.
2. Thepharmacokineticsmodel(Eqs.5)isusedtodeliverdrugtothelesions.Ineach
case we hold the intravascular concentration of drug sv constant for 2 h, then set
it to zero for eighteen more hours to allow washout.
3. DNA-boundAUCiscomputedbyre-dimensionalizings3 andtimeandintegrating
using Matlab. The result is then used in the pharmacodynamics model (Eq. 4)t o
compute cell inhibition. Nutrient (Eq. 1) is relevant when the nutrient effect is
employed.
Each lesion is produced based upon the same set of growth and vasculature parame-
ters (see Zheng et al. for a complete description), but randomness in the angiogenesis
algorithm and slightly different initial shapes produce different vasculatures and mor-
phologies. It is assumed that a tumor in vivo does not grow or regress appreciably
during the 20-h course of the therapy we are attempting to simulate, hence we stop
tumor and vascular growth during our in silico therapies. Intravascular concentrations
are calibrated in each case to produce a total cellular growth inhibition of 50%. This
concentration is referred to as the IC50. The sharp “square wave” delivery of drug
is perhaps a caricature of clinical bolus administration, but it allows for consistent
analysis and comparison of results.
OurﬁrstsetofexperimentscomparesDNA-bounddrugAUCdistributionsofdoxo-
rubicin and cisplatin under the baseline conditions in Table 1. We furthermore show
the homogenizing effect of doxorubicin retention on ﬁnal DNA-bound AUC [19].
We next investigate the impact of inhibition heterogeneity on dosing requirements,
paying particular attention to the nutrient effect for doxorubicin under baseline condi-
tions and improved penetration by, for example, removing hyaluronic acid [37,38].
In our third set of simulations we more deeply investigate the effect of doxorubicin
penetration therapies under three circumstances: baseline tumor density, high tumor
density, and baseline tumor density with Pgp efﬂux activity. These are chosen because
theydemonstrateaspectrumofpossibilitiesduetotheireffectoncellulardruguptake.
High tumor density increases uptake, while Pgp efﬂux decreases it. In order to simu-
late increased penetration, we increase Ds for doxorubicin from its baseline value to
5000 mm2 min−1 for a moderate increase, and 30,000 for the maximum increase, thus
matching the performance of cisplatin. To simulate high tumor density we increase ρ
by 50% to 1.5E9 cells ml−1. This has the effect of lowering the interstitial fraction F
to 0.22, which in turn increases k 
12 and k 
21 while leaving all other rates unchanged.
Pgpefﬂuxissimulatedbyincreasingk21 byafactorof10,whichhastheeffectofredu-
cing all intracellular compartment concentrations by approximately the same factor.
123Predicting drug pharmacokinetics and effect in vascularized tumors 497
This is consistent with results of [10] that show Pgp activity can reduce intracellular
concentrations of daunorubicin (an anthracycline related to doxorubicin) by up to a
factorof100.Inourfourthandﬁnalsetofexperimentsweinvestigatepermeabilization
therapy with respect to cisplatin, whereby a detergent, such as digitonin, or electro-
permeabilization is used to increase the permeability of cell membrane [35,72]. We
take an extreme case, increasing the rate constants k12 and k21 from baseline both by a
factor of 100. Note that this does not increase the limiting intracellular or DNA-bound
levels of drug attained in simulated monolayer, only the rate at which these come to
equilibrium. Thus highly permeabilized, DNA-bound max95 is attained at 3.4 h of
exposure; further permeabilization reduces this negligibly. For comparison, max95 is
greater than 27 h for unpermeabilized cells. This therapy is simulated under both in
vivo baseline and very high cell densities achieved by increasing the baseline density
75% to 1.75E9 cells ml−1. At this density, the interstitial fraction F drops to a mere
0.08. Both of these are further compared to monolayer results to probe the conditions
under which in vitro assays can be used to predict clinical efﬁcacy.
Although all treatments described are duplicated in each of the three in silico
tumors, we display only representative plots with appropriate summaries of all data.
The nutrient effect is only used where noted.
3.3 Results
First experiment We begin by examining DNA-bound AUC distributions at various
times in the baseline simulated lesions (each lesion corresponding to a column, I, II,
or III), shown in Fig. 2. From top to bottom, the times correspond to 2, 8, 14, and 20 h
post-bolus initiation. Levels are normalized relative to the average AUC within viable
lesion for comparison of heterogeneity. Although surrounding host tissue cells uptake
and bind with drug differently than cancer cells, we make no distinction in these color
plots; however, quantitative analytical results only consider DNA-bound drug within
viable lesion. The two left column sequences (Lesions I and II) show doxorubicin
AUC, while the rightmost column shows cisplatin. For both Lesions I and II, at 2 h
doxorubicin AUC is seen to be about three times the average (dark red) in the vicinity
of the vasculature, and almost 0 (blue) elsewhere. The distribution is only slightly
more homogeneous by 8 h. By 14 h the heterogeneity has lessened, with the peaks
close to the vasculature reaching only about 2.2. Finally, at the conclusion of washout
20hafterbolusinitiation,thedistributionhasbecome muchmorehomogeneous, with
peaks only reaching about 1.7 times the average. In contrast, cisplatin distribution
within Lesion III remains extremely homogeneous, right at the average, throughout
the entire treatment.
The probability distributions at the bottom, corresponding to AUC at 20 h post-
bolus initiation, allow for a more quantitative comparison. The two corresponding
to doxorubicin show much heterogeneity relative to cisplatin on the right. Using the
leftmost distribution as an example, the average DNA-bound AUC is found to be
6.04 fmole min. 25% of tumor cells receive less than 1.66 fmole min each, while 25%
oftumorcellsreceivemorethan9.54fmolemin.Theremaining50%ofthetumorcells
receive between these two values, a range of 7.88 fmole min. When normalized with
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Fig. 2 DNA-bound AUC at four times (rows 2, 8, 14, and 20 h) post-bolus initiation for three two-
dimensional simulated baseline tumor lesions (columns). I and II are doxorubicin, while III is cisplatin.
Results are normalized to average lesion AUC at the time taken to enable comparison of distribution
heterogeneities.Thickblackcontoursaretumorboundaries.Thinredcurvesarevasculature.Darkregionsare
necrotic areas. Each unit represents 200 mm. Bottom probability distributions show ﬁnal AUC distribution
at 20 h. A concise measure of heterogeneity is given by the inter-quartile range (IQR), depicted in the lower
left graph and explained in the text. Although AUC in host tissue is also shown in plots, analysis considers
only DNA-bound drug in viable lesion
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Table 2 Mean ± SD of the IC50 and the logs of their ratios with respect to monolayer treatments for
experiments to investigate the impact of drug and nutrient heterogeneity
Nutrient effect IC50,mono(mM) IC50(mM) log(IC50/IC50,mono)
Doxorubicin baseline
Off 0.175 0.482 ± 0.163 0.424 ± 0.138 (∗p < 0.05)
On 0.175 1.34 ± 0.874 0.830 ± 0.261 (∗p < 0.05)
Doxorubicin with penetration therapy
Off 0.175 0.197 ± 0.0172 0.0511 ± 0.0371 (p > 0.05)
On 0.175 0.371 ± 0.0356 0.325 ± 0.0407 (∗p < 0.05)
Cisplatin baseline
N/A 7.05 7.14 ± 0.0757 0.00529 ± 0.00462 (p > 0.05)
IC50,mono is the IC50 of baseline cells in monolayer. At the 5% signiﬁcance level using a one-tailed t test,
the average log ratio for cisplatin does not exceed 0. On the other hand, in three of the four experiments
with doxorubicin, they do. Paired one-tailed t tests show that the average logIC50 ratios for doxorubicin
with the nutrient effect are greater than that without regardless of penetration therapy
respect to the average and expressed as a percent, this yields 131% (the interquartile
range,orIQR),andgivesaconcisemeasureofdistributionheterogeneity(thecloserto
0,themorehomogeneous).IQR’saregivenateachoftheothertimepointsaswell.All
threetumors,despitevariedlesionandvasculaturemorphologies,demonstratesimilar
results (not all shown). Doxorubicin AUC IQR’s typically lessen from about 250% at
2 h to 150% at 20 h; cisplatin AUC IQR’s drop from about 10 to 2%. Interestingly, in
the run shown, the heterogeneity for cisplatin increases slightly in the last frame. This
happens in one of the other two tumors as well.
Second experiment We next investigate the impact of drug and nutrient heterogeneity
on cell inhibition distributions and IC50’s. Bolus administrations are simulated for
cisplatin using baseline lesions exactly as in Fig. 2. The PD model (Eq. 4) is then used
to calculate cell inhibition. For doxorubicin we use baseline lesions as well as lesions
in which drug penetration therapy is applied. Experiments for dox are run both with
and without the nutrient effect.
A table of average IC50’s and log(IC50/I C 50,mono)’s for these experiments is given
inTable2.Hereandthroughout thispaper “IC50,mono”referstobaselinecellsexposed
in monolayer and serves as a reference. Note that, as these are simulated monolayer
exposures, IC50,mono is deterministic. Figure 3 shows a typical nutrient proﬁle, using
Lesion II as an example with an IQR of 36%. This measurement is completely analo-
goustothatusedinFig.2exceptthathereitisappliedtonutrientdistributionandthere
isnonormalizationsincenutrientlevelsareboundedabsolutelyfrom0to100percent,
the level within the vasculature, itself. Nutrient IQR’s for the other two lesions are
within 2% of this value.
At the 5% signiﬁcance level, one-tailed t tests show that the average logIC50 ratio
is not greater than 0 for cisplatin, underscoring the homogeneity of its distribution. In
contrast,outofthefourexperimentsperformedfordoxorubicinfromthecombinations
of nutrient effect and penetration therapy, three indicate that the average log ratios are
greater than 0 at the 5% signiﬁcance level. Within this group of four we can analyze
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Fig. 3 Contour plot shows
nutrient distribution in Lesion II
demonstrating signiﬁcant
heterogeneity. Other lesions are
similar
the strength of the nutrient effect. For the baseline lesion, the nutrient effect increases
the logIC50 ratio by 0.406 units (a factor of about 2.5). For the lesion with penetration
therapy, the increase is 0.274 units (a factor of about 1.9). Paired t tests show that
these differences are signiﬁcant at the 5% level.
Cell inhibition distributions closely mirror their AUC distributions, with that of
cisplatin being virtually uniform at 50% inhibition throughout. Conversely, doxoru-
bicin displays heterogeneity, increased with the addition of the nutrient effect. Using
Lesion II as a representative example for doxorubicin, the upper block of frames in
Fig.4demonstratestheinhibitiondistributionsforthebaselinelesionwithandwithout
the nutrient effect. While the broadening of the cumulative probability plot as well as
a comparison of the color distribution plots indicate that the nutrient effect increases
heterogeneity, inhibition IQR is reduced from 81 to 77% (again, not normalized).
The effect of penetration therapy in the lower block of frames is readily apparent.
IQR’s, color plots, and probability graphs all indicate more uniform inhibition, ran-
ging moderately from 35 to 65%. Again we see increased heterogeneity in the plots
with the addition of the nutrient effect. This time the IQR also reﬂects the increase.
Lesions I and III yield similar results.
Third experiment In our third set of simulations, we investigate the effect of the-
rapies designed to improve doxorubicin penetration under several combinations of
drug/interstitum diffusivities, cell densities, and drug efﬂux activities (e.g., Pgp).
Figure 5 gives bar graphs of (a) logIC50 ratios and (b) AUC interquartile ranges
for three scenarios. The leftmost triplet corresponds to baseline tumor density and
no efﬂux, resulting in a condition of “normal” cellular uptake. The middle triplet
corresponds to high density with no efﬂux, a condition of high uptake. The rightmost
correspondstobaselinedensitywithefﬂux,aconditionoflowuptake.ForthelogIC50
ratio(a),inthebaselinetumorcasethereisachangeof−0.388logunitsingoingfrom
no removal of hyaluronic acid to almost complete removal. When density is increa-
sed, the change increases to −0.709; however, when Pgp efﬂux is activated, ANOVA
reveals there is no statistical difference, and in fact, the measured change is posi-
tive. Results are similar when the nutrient effect is included, with all bars essentially
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Fig. 4 (Upper block) Cell growth inhibition proﬁle of Lesion II at baseline settings with and without
the nutrient effect after bolus administration depicted in Fig. 2. Probability plot and IQR are now of
inhibition distribution and are not normalized with respect to any average. Although the IQR indicates
decreased heterogeneity with the nutrient effect, both the color distribution plot and the probability plot
indicate increased heterogeneity as is evidenced by the broadening of the curve. (Lower block)T h es a m e
experiment, except with doxorubicin penetration increased. Now both the plots and IQR show increased
heterogeneity. The appropriate IC50 is used in each experiment
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Fig. 5 The effect of increasing doxorubicin penetration on a log(IC50/IC50,mono) and b interquartile
rangeshowninthreecases:baselinetumor(exceptingpenetrationtherapy),high-densitytumor,andnormal
density tumor with Pgp efﬂux. High density has the effect of increasing drug uptake, while Pgp efﬂux has
the opposite effect. Three replications per bar with standard deviations and results of ANOVA displayed
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Fig. 6 Effect of permeabilization therapy with respect to cisplatin is shown in three cases. Bars are of
log(IC50,perm/IC50,unperm)where“perm”and“unperm”correspondtopermeabilizedandunpermeabilized
conditions.Threereplicationsperbar withresultsoftwo-tailedt testsrelativetomonolayerdisplayed.While
there is a statistical difference at the 0.05 signiﬁcance level for the high-density tumor, this disappears at
the 0.01 signiﬁcance level
increased by a constant, approximately 0.37. For the AUC interquartile range (b),
it is seen that heterogeneity is greatest in the high density case and least in the Pgp
efﬂuxcase.Withineachtriplettheheterogeneitydecreaseswithincreasingpenetration
therapy, as expected. The magnitudes of change mirror those for the logIC50 ratios,
with the baseline case experiencing a moderate change (from 146 to 13%), the high
density case experiencing a dramatic change (from 217 to 52%), and the Pgp efﬂux
case experiencing the least change (from 57 to 4%).
Fourthexperiment Inourfourthandﬁnalsetofsimulationsweinvestigatetheeffectof
permeabilization therapy vis-a-vis cisplatin. Figure 6 shows log(IC50,perm/
IC50,unperm) for three cases: monolayer, in vivo with baseline cell density, and in
vivo with high cell density. Here, the subscripts “perm” and “unperm” denote the
application or withholding of permeabilization therapy. Permeabilization results in a
decrease of 0.154 logIC50 units for simulated monolayers, i.e., a reduction of IC50 by
a factor of 0.7, and is thus effective in vitro. An interesting question is whether this
carries over in vivo, i.e., whether a monolayer assay can be used to predict clinical
efﬁcacy. Improvements for the two in vivo simulations are comparable to monolayer
results, with all three log-differences about −0.14, and no statistical difference bet-
ween improvement for the baseline case and for monolayer at the 5% signiﬁcance
level using a two-tailed t test.
4 Discussion
In agreement with experimental observation, our simulations show that heterogenei-
ties of drug, nutrient, and oxygen, caused in part by irregular vasculature and lesion
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morphology,existandcansigniﬁcantlyimpacttherapeuticresults.Moreover,thesense
and magnitude of their inﬂuence is not always intuitively obvious. A good example of
this is that, despite its well-noted penetration difﬁculties, doxorubicin performs well
clinically. Our simulations show that this may be somewhat explained by its retention
intissueremovedfromvasculature,causinghomogeneityofexposuretoincreaselong
afterthebolushasbeenterminated(Fig.2).Thisphenomenonhasbeenexperimentally
veriﬁedin[19]withspheroids.Becauseofthis,theresultingcellinhibitiondistribution
is more homogenous than would otherwise be expected. On the other hand, cisplatin
maintains an homogenous DNA-bound distribution at all times from bolus initiation
to 20 h later, resulting in an extremely uniform cell inhibition distribution. This result,
as well as the near equality of its IC50 and IC50,mono demonstrated in Table 2, has also
been experimentally veriﬁed with spheroids [18,32,37].
While retention in tissue contributes to the performance of doxorubicin in vivo,
Table 2 demonstrates that its heterogeneity of distribution contributes to increased
serum drug concentrations to match the same cell inhibition in monolayer. In one
case, the average amount of drug increases by nearly one log unit. It is reasonable to
expect that heterogeneity of nutrient, resulting in hypoxia and hypoglycemia, should
compound this problem for doxorubicin. Indeed, this is the case as can be seen by the
approximate doubling of the IC50’s (0.482 mM vs. 1.34 and 0.197 vs. 0.371) when the
nutrienteffectisapplied.Bygraphicallyandquantitativelyshowingcorrespondingcell
inhibitiondistributions.Figure4offersfurtherinsightintothesephenomena.Itiseasily
seenthatcellinhibitiondistributionsareasheterogeneousastheircorrespondingDNA-
boundAUCdistributions,withareasoflesionremovedfromvasculatureexperiencing
reduced cell inhibition. An examination of the probability plots in the upper block,
corresponding to baseline lesions, shows that a full 24% of viable lesion undergoes no
inhibitionatall.Itisclearfromthesegraphsthatpenetrationtherapygreatlydecreases
heterogeneity of cell inhibition (and commensurately, IC50) as does removal of the
nutrient effect. The latter may be clinically feasible through, for example, carbogen
breathing or recombinant human Epo (rHuEPO) administration [63,75].
One puzzling behavior is that while both the color and probability plots demons-
trate consistently increased heterogeneity brought about by the nutrient effect (as is
evidenced by the broadening of the probability curves), the IQR actually decreases in
thebaselinecasefrom81to77%.ThisoccurswithLesionsIandIIIaswell.Asolution
to the mystery is obtained by noticing that, absent the nutrient effect, a large portion
of the tumor either experiences no inhibition (about 24%, which is distant from the
vasculature) or an already heterogeneous inhibition (about 31%). The remaining 45%
receives a near homogeneous level of inhibition (the vertical portion of the curve),
and this fraction corresponds to tissue close to the vasculature. Thus, the only signi-
ﬁcant heterogeneity that can be induced by the nutrient effect is within this fraction.
Indeed, it is just this part of the curve that broadens in the second probability distribu-
tion, indicating greater heterogeneity, as expected. As the IQR is designed to measure
heterogeneity somewhat more globally, it misses—in fact, misdiagnoses—the change
occurring within this fraction.
In addition to dosing requirements, there is a second and subtler reason to consi-
der heterogeneity of the inhibition distribution when treating clinical tumors. Hete-
rogeneities in microenvironmental conditions have been linked to increased lesion
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fragmentation and invasiveness [12,25,39,45,55]. While the mechanisms underlying
this phenomenon are complex, involving myriad protein signaling events and activi-
ties at the cellular level, they may at least partly rely on gross lesion effects, including
those caused by drug administration.
Figure 5 shows what might be expected from therapies that increase doxorubicin
penetration by, for example, removing hyaluronic acid. As expected, for the baseline
tumors, greater homogeneity and level of AUC is achieved, resulting in reductions
of IC50. This effect has been experimentally veriﬁed using spheroids [37,38]. That it
should be more pronounced for high-density in silico tumors and completely absent
in the presence of Pgp efﬂux is intriguing. A potential explanation is availed by sim-
plifying the pharmacokinetics model (Eqs. 2), reducing it to the one-dimensional,
one-compartment steady state diffusion equation 0 = D∇2s − ks with diffusivity D
and uptake rate k. In two dimensions, a segment of blood vessel acting as a source
next to a section of tissue approximates the one-dimensional case. This equation
has one governing parameter, the characteristic diffusion length L =
√
D/k, and a
(non-unique) solution sv exp(−x/L), where x is distance from the source and sv is the
constantlevel ofdruginthevasculature. Consideringasectionoftissueofthicknessd
next to a vessel and a ﬁxed exposure time, average AUC is proportional to the integral
d 
0
sv exp(−x/L)dx = svL(1 − exp(−d/L)). (6)
Let AUC50 be the ﬁxed average AUC required for ﬁfty percent cell inhibition. Then,
ignoring the constant of proportionality,
AUC50 = IC50L(1 − exp(−d/L)). (7)
Increasing the diffusivity to simulate penetration therapy results in an increased cha-
racteristic length CL, where C > 1, and hence a new IC50. The ratio of IC50’s is
therefore
AUC50/CL(1 − exp(−d/CL))
AUC50/L(1 − exp(−d/L))
=
(1 − exp(−d/L))
C(1 − exp(−d/CL))
, (8)
which approaches 1 as L →∞ , and approaches 1/C as L → 0. Now, increasing cell
density has the effect of increasing k, resulting in a smaller L, thus manifesting the
differential in IC50’s. Conversely, activating Pgp efﬂux has the effect of decreasing k,
resulting in a larger L, thus nullifying the differential.
That something along these lines is probably happening is demonstrated in Fig. 5b
bythegenerallyhighIQR’sforthehighdensitycaseversusthelowIQR’sforthePgp,
and the large change in the high density triplet versus the Pgp triplet. Indeed, there is
experimental evidence that Pgp and other transporters might facilitate drug transport
further away from vasculature [77]. This could be an important point when deciding
uponappropriatetherapiesfortumorsexhibitingdifferentcharacteristicssuchasefﬂux
mechanismsandrelativelyhighorlowdensities.Anytherapyinvolvesrisk.Theremay
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be less to gain under certain conditions, advising that the therapy not be performed or
perhaps, that concomitant therapy be performed designed to optimize conditions.
The great homogeneity of both cisplatin AUC and cell inhibition demonstrated in
Fig. 2 and Table 2 indicate that in vitro assays using this drug may have relatively high
positive predictive accuracy. While our simulations do not yield enough resolution
to claim that the results herein answer this question, the outcome shown in Fig. 6
is of interest. There is no statistical difference at the 0.01 signiﬁcance level between
improvementobtainedbypermeabilizationtherapyinthesimulatedtumors(evenvery
denseones)andmonolayer.Thiscomparesfavorablywiththeﬁndingsof[72]inwhich
the improvement obtained via cisplatin permeabilization therapy in vitro is strongly
reﬂected by the improvement in isolated lung perfusion in rats.
Whileitcanandshouldbearguedthatthesimulationshereinfailtoaccountforsome
(many!) critical aspects of tumor growth and drug response (such as clonal heteroge-
neity, cell phase sensitivity, and signaling pathways) and that parameter settings may
insomecasesbeinexact,itshouldnotbeconcludedthattheseshortcomingsinvalidate
characteristics the simulations have revealed. Indeed, we have correctly post-dicted
several results: that doxorubicin retention results in a more uniform AUC and cell
inhibition than would otherwise be indicated by its penetration difﬁculties [19]; that
Pgpandothertransportersmightfacilitatedrugpenetrationintolesiontissue[77];that
cisplatinachievesahighlyuniformAUC,anditscellularinvitromonolayerinhibition
can closely match that of in vitro spheroids [18,32,37]; and that improvement due to
cisplatin permeabilization therapy in vitro has the potential to predict improvement
in vivo [72]. Through the model we have provided evidence that not only do macro-
scopicenvironmentalconditions,namely,drugandnutrientdistributionheterogeneity,
potentiallygreatlyimpacttherapeuticefﬁcacy,butalsothattheoutcomeoftherapeutic
strategies can depend upon them in nonlinear and a priori unpredictable ways. The
results of our third set of experiments (doxorubicin penetration therapy) provide an
example. In light of this, it would be prudent to devote attention to factors residing at
coarser and more global scales than solely the genetic.
One of our broader goals is to demonstrate how increasingly sophisticated in silico
technology, driven by mathematical modeling and calibrated with experimental data,
can and is being developed to provide an alternate investigative and clinical tool com-
plementary to traditional methods [6,24,61,62,67]. It can well be imagined that were
doxorubicin and cisplatin discovered today, the in vivo simulations herein presented
couldbeusedtoanticipatetheirlesion-andcellular-scalepharmacokinetics,helpingto
reﬁne clinical trial design and lower costs. In clinical application, the results could be
used to guide therapeutic strategy. For example, any risks associated with doxorubicin
penetration therapy could be minimized if it were known that the patient’s tumor were
expressingPgporotherwisehadloweredcellularuptake,accordingtotheresultsgiven
in Fig. 5. With further development, we anticipate that in silico models and methods
similar to those in this paper will become increasingly accurate and useful. Towards
that end we are working on incorporating a more veridical model of vasculature along
the lines of McDougall and Stephanou, in which blood ﬂow plays a key role in the
formation of vasculature [46,69]. We are furthermore developing 3D models, which
are proving successful at accurately simulating morphological evolution [23]. One
area of special interest is that of liposomal and nanovectored delivery. These have
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the potential of unprecedented accuracy and speciﬁcity of delivery [22]. It would be
interesting to adapt the PKPD model herein, paying particular attention to transport
in and extravasation from blood vessels [28], to see what predictions can be made.
The power of in vitro experimentation lies in its ease of implementation while
remaininginthebiologicalrealm.Byitsverynature,invitroexperimentationattempts
to reﬁne and isolate. Yet, much of what happens in vivo is the result of a nonlinear
system whose behavior is more than the sum of its parts. The power of in silico
simulation lies in its ability to integrate components into a virtual system capable of
reproducing such behavior, implicitly taking into account circuits of information ﬂow
difﬁcult to explicitly analyze. Accurately calibrated and rigorously validated, such
an integrated model could provide a “dry-lab” to be used as a powerful complement
to the traditional wet-lab in fundamental research, drug discovery, and the clinic.
It could be used to probe scenarios and test hypotheses that are either difﬁcult or
impossible to instantiate in the body. Results could then suggest supportive in vitro
and in vivo experimentation, the end result being new therapeutic targets or strategies.
Simultaneously, weaknesses (or strengths!) of the in silico model could be uncovered
and addressed. Computational models have the potential to facilitate an era of great
discovery and progress in understanding and treating cancer, and providing new hope
to its victims.
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